Drugs / Reh-acteoside
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02662283 | May → Nov 2016 | IgA glomerulonephritis | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Reh-acteoside | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02662283 ↗ |
| Route | Oral | “Oral take reh-acteoside (0.4g bid) for 8 weeks” NCT02662283 ↗ |